

Filed On Behalf Of: Novartis AG

By: Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**PAR PHARMACEUTICAL, INC.,  
BRECKENRIDGE PHARMACEUTICAL, INC. AND  
ROXANE LABORATORIES, INC.**

Petitioners,

v.

**NOVARTIS AG,**  
Patent Owner

---

Case IPR2016-00084<sup>1</sup>  
U.S. Patent 5,665,772

---

**PATENT OWNER'S OBJECTIONS TO PETITIONERS'  
DEMONSTRATIVE EXHIBITS FOR ORAL HEARING**

---

<sup>1</sup> Breckenridge Pharmaceutical, Inc. was joined as a party to this proceeding via a Motion for Joinder in IPR2016-01023; Roxane Laboratories, Inc. was joined as a party via a Motion for Joinder in IPR2016-01102.

Pursuant to the Board’s January 17, 2017 Order regarding the Trial Hearing, Patent Owner Novartis AG (“Novartis”) objects to the following demonstratives served on January 24, 2017, by Petitioners Par Pharmaceuticals, Inc., Roxane Laboratories, Inc., and Breckenridge Pharmaceutical, Inc. (“Petitioners”) on the grounds set forth below. Pursuant to the Board’s Order, the parties held a meet and confer on January 30, 2017, to discuss their respective objections to demonstrative exhibits, but were unable to resolve the objections set forth below.

**I. Novartis’s Objections To Petitioners’ Slides Containing New Arguments Not Presented In The Petition Or Reply**

**Slide 35:** Novartis objects to the second bullet and the box that follows thereafter in Slide 35, set forth below:

• Novartis admits Lemke teaches an “ethyleneoxy” group would have “net zero” impact on solubility due to hydrophilicity ( $\pi$  value) POR 11; Klibanov Decl. ¶¶ 45-46 & n.5

↑ favorable entropy + 0 effect on hydrophilicity → ↑ solubility

Reply 10-11

Novartis objects to this bullet and box as an improper new argument because Petitioners have not previously argued in the Petition or Reply, nor has Novartis admitted in the Patent Owner Response (Paper 27 at 11) or Klibanov Declaration (Ex. 2092 ¶¶ 45-46 & n.5), that Lemke’s solubility teachings are limited to “hydrophilicity,” Petitioners have not previously included the equation in the box above in the Petition or Reply, and the Petitioners have not previously cited or relied on Klibanov Decl. ¶ 46 & n.5.

**Slides 43, 51, 53:** Novartis objects to item number 2 in Slides 43, 51, and 53, set forth below:

**2. Everolimus did not satisfy any long-felt but unmet need**

Novartis objects to item number 2 as an improper new argument because Petitioners have not disputed that everolimus satisfied a long-felt but unmet need for an immunosuppressant regimen for liver transplant recipients, as set forth in the Patent Owner Response, Paper 27 at 68.

**Slide 49:** Novartis objects to the first bullet in Slide 49, set forth below:

- Cyclosporine interferes with metabolism of everolimus and rapamycin, leading to increase in plasma concentrations

Reply 25; Ratain Decl. ¶ 46

Novartis objects to this bullet as an improper new argument because Petitioners have not previously argued in the Petition or Reply that “[c]yclosporine interferes with metabolism of everolimus and rapamycin, leading to increase in plasma concentrations,” and Petitioners’ citation to Ratain Decl. ¶ 46 as support for their reliance on these exhibits would constitute an improper incorporation by reference.

**Slide 52:** Novartis objects to the bullets under the second heading in Slide 52, set forth below:

- Need remains for breast and renal cell cancer treatments
- Other treatments explicitly have been shown to be superior to everolimus

Reply 26-27; Ratain Decl. ¶ 111

Novartis objects to each of these bullets as improper new arguments because Petitioners have not previously argued in the Petition or Reply that a need remains for breast cancer treatment or that other treatments for breast cancer are superior to everolimus.

## II. **Novartis's Objections To Petitioners' Slides Citing New Evidence Not Previously Cited In The Petition Or Reply**

**Slide 37:** Novartis objects to the second sub-bullet in Slide 37, set forth below:

- Increase in internal entropy leads to increase in solubility in examples of nonideal solutions (Ex. 1117 Schwartz at 254, Table II, Table III)

Reply 16; Jorgensen Supp. Decl. ¶¶ 96-99

Novartis objects to this sub-bullet and citation to Ex. 1117 as an improper new argument because Petitioners have not previously cited Ex. 1117 in the Petition or Reply.

**Slide 46:** Novartis objects to the sub-bullets listed under the third main bullet in Slide 46, set forth below:

- Rapamycin *has* clinical activity in each of the approved tumor indications

Reply 22-23; Ratain Decl. ¶¶ 62-100

- Breast cancer (*E.g.*, Ex. 2178, Ex. 2177) Ratain Decl. ¶¶ 64-75
- Renal cell carcinoma (Ex. 2173, Ex. 1087) Ratain Decl. ¶¶ 83-87
- NETs (Ex. 1088, Ex. 2163) Ratain Decl. ¶¶ 76-82
- SEGA (Ex. 1098, Ex. 1099) Ratain Decl. ¶¶ 96-100
- Renal angiomyolipoma (Ex. 1093) Ratain Decl. ¶¶ 88-95

Novartis objects to Petitioners' citation to and discussion of Exs. 2178, 2177, 2173, 1087, 1088, 2163, 1098, 1099, and 1093 in these sub-bullets as an improper new argument because Petitioners have not previously cited these exhibits in the Petition or Reply to assert that everolimus's antitumor activity is no different than rapamycin's, and Petitioners' citation to Ratain Decl. ¶¶ 62-100 as support for their reliance on these exhibits constitutes an improper incorporation by reference.

**Slide 48:** Novartis objects to Petitioners' citation of Ex. 1120 and Fig. 1 in Slide 48, set forth below:

Fig. 1. The mTOR pathway.

Reply 23; Ratain Decl. ¶¶ 101-108; Ex. 1120 at Fig. 1

Novartis objects to Petitioners' citation of Ex. 1120 and reliance on Fig. 1 of Ex. 1120 as an improper new argument because Petitioners have not previously cited Ex. 1120 in the Petition or Reply, and Petitioners' citation to Ratain Decl. ¶¶ 101-108 as support for their reliance on these exhibits constitutes an improper incorporation by reference.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.